These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 19442491

  • 1. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    Pae CU, Serretti A, Chiesa A, Mandelli L, Lee C, Lee C, Kim J, De Ronchi D, Paik IH.
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, Lee MS.
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, Lissens J, Sanchez R.
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M, Kosaka H, Takahashi T, Yatuga C, Asano M, Tanaka Y, Ueno K, Okazaki R, Omori M, Hiratani M, Tomoda A, Wada Y.
    Clin Neuropharmacol; 2013 Dec; 36(5):151-6. PubMed ID: 24045605
    [Abstract] [Full Text] [Related]

  • 17. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
    Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H.
    J Clin Psychopharmacol; 2009 Aug; 29(4):394-5. PubMed ID: 19593185
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
    Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ortiz-Garcia de la Foz V, Martínez-Garcia O, Valdizan EM, Vazquez-Barquero JL.
    J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
    [Abstract] [Full Text] [Related]

  • 20. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B.
    CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.